	US 12,448,448 B2
	Anti-PD-1 antibodies and uses thereof
Mark Cornfeld, Philadelphia, PA (US); Naimish Bharat Pandya, Rockville, MD (US); Jon Marc Wigginton, Rockville, MD (US); Ross La Motte-Mohs, Rockville, MD (US); and Bradley James Sumrow, Rockville, MD (US)
Assigned to Incyte Corporation, Wilmington, DE (US); and MacroGenics, Inc., Rockville, MD (US)
Filed by Incyte Corporation, Wilmington, DE (US); and MacroGenics, Inc., Rockville, MD (US)
Filed on Jun. 18, 2019, as Appl. No. 16/444,691.
Claims priority of provisional application 62/756,319, filed on Nov. 6, 2018.
Claims priority of provisional application 62/687,673, filed on Jun. 20, 2018.
Prior Publication US 2020/0095322 A1, Mar. 26, 2020
Int. Cl. C07K 16/28 (2006.01); A61K 9/00 (2006.01); A61K 39/00 (2006.01); A61P 35/00 (2006.01); A61P 35/04 (2006.01)

CPC C07K 16/2818 (2013.01) [A61K 9/0019 (2013.01); A61P 35/00 (2018.01); A61P 35/04 (2018.01); A61K 2039/505 (2013.01); A61K 2039/545 (2013.01); C07K 2317/24 (2013.01); C07K 2317/565 (2013.01)]

6 Claims

1. A method of treating Merkel cell carcinoma in a human subject in need thereof, the method comprising administering to the human subject a therapeutically effective amount of an antibody that binds to human PD-1, wherein the antibody comprises a heavy chain and a light chain, wherein the heavy chain comprises the amino acid sequence set forth in SEQ ID NO:2 and the light chain comprises the amino acid sequence set forth in SEQ ID NO:3,

and wherein the antibody is administered at a dose of 500 mg once every four weeks.